Exact Sciences Corp. (Nasdaq:EXAS), a company focused on the early detection and prevention of colon cancer, is pleased to welcome Daniel J. Levangie, Lionel N. Sterling and David A. Thompson to the company’s board of directors.

Mr. Levangie brings corporate leadership and diagnostic test development experience to the board. Mr. Levangie is president, chief executive and a director of Keystone Dental Inc. He also is a director of Dune Medical Devices Inc., ev3 Inc., and HyperMed Inc. He previously held board and executive positions at Cytyc Corp. and Hologic Inc. Mr. Levangie will serve as a member of the company’s Corporate Governance and Nominating Committee, and Innovation and Technology Committee.

Mr. Sterling joins the board with an impressive record of corporate strategy, finance and operations experience. Mr. Sterling is president of Equity Resources Inc. He also is a director of Molecular Insight Pharmaceuticals Inc. He previously served as a director of i-STAT Corp., Rayovac Corp., Third Wave Technologies Inc., United Brands Co. and ZiLOG Inc. Mr. Sterling will serve as chair of the company’s Audit Committee.

Mr. Thompson adds his extensive knowledge of the health care industry as well as strategic experience to the board. Mr. Thompson retired from Abbott Laboratories in 1995, where he served for more than 30 years in a variety of corporate officer positions including senior vice president and president of Abbott Laboratories Diagnostic Division. Mr. Thompson was previously chairman and lead independent director of Third Wave Technologies Inc. and lead director of St. Jude Medical Inc. Mr. Thompson will serve as chair of the company’s Corporate Governance and Nominating Committee, and as a member of the company’s Compensation Committee.

Mr. Thompson is expected to be elected to the Exact Sciences’ board by the company’s stockholders at the company’s 2010 annual stockholders meeting taking place today and will fill the seat of Sen. Connie Mack III, who is not standing for re-election at the meeting. Mr. Levangie and Mr. Sterling were appointed by the board and will fill the seats of Edwin M. Kania, Jr. and Lance Willsey, M.D., who will resign from the board at the conclusion of the company’s board meeting today. James P. Connelly, who has served as an Exact Sciences director since April 2009, has been elected chairman of the board and will succeed Patrick J. Zenner, who will resign from the board at the conclusion of the company’s board meeting today.

About Exact Sciences Corp.

Exact Sciences Corp. is a molecular diagnostics company focused on colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer. For more information about Exact Sciences, please visit the company’s website at www.exactsciences.com.

Certain statements made in this press contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or other comparable terms. Forward-looking statements in this press release may address the following subjects among others: statements regarding the sufficiency of our capital resources, expected operating losses, expected license fee revenues, expected research and development expenses, expected general and administrative expenses and our expectations concerning our business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports of Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.